198 related articles for article (PubMed ID: 34047177)
21. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
Chen L; Yan HX; Liu XW; Chen WX
Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
[TBL] [Abstract][Full Text] [Related]
22. Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Schwarz UI; Woldanski-Travaglini M; Swanston V; Mikhail M; Cacciotti C; Cairney E; Patel S; Seelisch J; Tole S; Wilejto M; Tirona RG; Kim RB; Zorzi AP
Clin Pharmacol Ther; 2023 Jun; 113(6):1326-1336. PubMed ID: 36932910
[TBL] [Abstract][Full Text] [Related]
23. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
[TBL] [Abstract][Full Text] [Related]
24. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Al-Modhwahi I; Andersen MK; Behrendtz M; Forestier E; Hasle H; Heyman M; Kristinsson J; Nersting J; Nygaard R; Svendsen AL; Vettenranta K; Weinshilboum R;
Blood; 2009 Jun; 113(24):6077-84. PubMed ID: 19224761
[TBL] [Abstract][Full Text] [Related]
25. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
[TBL] [Abstract][Full Text] [Related]
26. Incorporation of 6-thioguanine nucleotides into DNA during maintenance therapy of childhood acute lymphoblastic leukemia-the influence of thiopurine methyltransferase genotypes.
Ebbesen MS; Nersting J; Jacobsen JH; Frandsen TL; Vettenranta K; Abramsson J; Wesenberg F; Schmiegelow K
J Clin Pharmacol; 2013 Jun; 53(6):670-4. PubMed ID: 23585236
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
28. DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
Toksvang LN; Grell K; Nersting J; Degn M; Nielsen SN; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Lepik K; Vaitkevičienė G; Griškevičius L; Quist-Paulsen P; Vora A; Moorman AV; Murdy D; Zimmermann M; Möricke A; Bostrom B; Joshi J; Hjalgrim LL; Dalhoff KP; Als-Nielsen B; Schmiegelow K
Leukemia; 2022 Jan; 36(1):33-41. PubMed ID: 34175901
[TBL] [Abstract][Full Text] [Related]
29. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
30. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
[TBL] [Abstract][Full Text] [Related]
31. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
32. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
[TBL] [Abstract][Full Text] [Related]
34. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
[TBL] [Abstract][Full Text] [Related]
35. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
36. Liquid chromatography-tandem mass spectrometry quantification of 6-thioguanine in DNA using endogenous guanine as internal standard.
Jacobsen JH; Schmiegelow K; Nersting J
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Jan; 881-882():115-8. PubMed ID: 22178190
[TBL] [Abstract][Full Text] [Related]
37. Quantification of Thioguanine in DNA Using Liquid Chromatography-Tandem Mass Spectrometry for Routine Thiopurine Drug Monitoring in Patients With Pediatric Acute Lymphoblastic Leukemia.
Choi R; Chun MR; Park J; Lee JW; Ju HY; Cho HW; Hyun JK; Koo HH; Yi ES; Lee SY
Ann Lab Med; 2021 Mar; 41(2):145-154. PubMed ID: 33063676
[TBL] [Abstract][Full Text] [Related]
38. The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K; Heyman M; Gustafsson G; Lausen B; Wesenberg F; Kristinsson J; Vettenranta K; Schroeder H; Forestier E; Rosthoej S;
Leukemia; 2010 Apr; 24(4):715-20. PubMed ID: 20130603
[TBL] [Abstract][Full Text] [Related]
39. Maintenance therapy of childhood acute lymphoblastic leukemia revisited-Should drug doses be adjusted by white blood cell, neutrophil, or lymphocyte counts?
Schmiegelow K; Nersting J; Nielsen SN; Heyman M; Wesenberg F; Kristinsson J; Vettenranta K; Schrøeder H; Weinshilboum R; Jensen KL; Grell K; Rosthoej S
Pediatr Blood Cancer; 2016 Dec; 63(12):2104-2111. PubMed ID: 27447547
[TBL] [Abstract][Full Text] [Related]
40. [Progress of Research on 6-Thioguanine versus 6-Mercaptopurine in childhood ALL].
Hou YJ; Zhao L; Liu XX; Ma YY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):622-6. PubMed ID: 27151041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
